BrainCells Inc. (BCI), a biopharmaceutical company utilizing its platform technology to identify and develop compounds that promote the growth of new neurons for the treatment of central nervous system (CNS) diseases, announced that it has initiated a Phase 2a clinical trial with its lead product candidate, BCI-540, for the treatment of depression with anxiety.
Popularity: unranked [?]
Related posts:
- CeNeRx BioPharma Initiates Phase II Clinical Trial Of Its Novel Antidepressant Agent Tyrima(TM)
- CeNeRx BioPharma Initiates Phase II Clinical Trial Of Its Novel Antidepressant Agent Tyrima(TM)
- DOV Pharmaceutical, Inc. Initiates Phase II Clinical Trial In Patients With Major Depressive Disorder
- Naurex Inc. Initiates Phase I Clinical Trial Of Its Novel Mechanism NMDA Modulator GLYX-13 In Treatment-Resistant Depression
- Naurex Inc. Initiates Phase I Clinical Trial Of Its Novel Mechanism NMDA Modulator GLYX-13 In Treatment-Resistant Depression
Comments
No Responses to “BrainCells Inc. Initiates Phase 2 Clinical Trial With BCI-540 For Depression With Anxiety”